MD&M East

CMS Could Expand National Coverage for TAVR Thanks to Edwards

Edwards Lifesciences has persuaded CMS to publish an updated tracking sheet for TAVR national coverage analysis. The move is causing CMS to reconsider its previous stance on covering transcatheter ...
Medscape

TAVR vs Surgery in Low-Risk Patients: 7-Year Outcomes Show Equivalent Results

SAN FRANCISCO — After 7 years, transcatheter aortic valve replacement (TAVR) remains equivalent to surgery with respect to durability and safety in low-risk patients, a finding that may blunt ...
Healio

TAVR for asymptomatic severe aortic stenosis superior to surveillance regardless of age

Please provide your email address to receive an email when new articles are posted on . The benefit of TAVR vs. clinical surveillance for patients with asymptomatic severe aortic stenosis did not vary ...
FierceBiotech

Edwards Lifesciences nets FDA approval opening up TAVR to patients before they show symptoms

Edwards Lifesciences has claimed a groundbreaking approval from the FDA that opens up its minimally invasive heart valve implants to patients before they begin to show cardiac symptoms. The company ...
Seeking Alpha

Edwards Lifesciences upped to Buy at Stifel on TAVR growth

Edwards Lifesciences (NYSE:EW) traded higher on Thursday after Stifel upgraded the heart device maker to Buy from Hold, citing a turnaround in its position in the market for transcatheter aortic valve ...
BioWorld

Edwards seeks a TAVR two-fer in Medicare coverage petition

Edwards Lifesciences Corp., of Irvine, Calif., petitioned the Centers for Medicare & Medicaid Services to revise the Medicare coverage policy for transcatheter aortic valve replacement (TAVR) devices ...
Medscape

TAVR Beats Surveillance for Asymptomatic Aortic Stenosis

WASHINGTON, DC — Transcatheter aortic valve replacement (TAVR) is superior to surveillance in patients with severe but asymptomatic aortic stenosis with no apparent cost in adverse events, according ...
Nasdaq

Edwards Lifesciences announces results from EARLY TAVR trial

Edwards Lifesciences (EW) announced results from the EARLY TAVR Trial, the first randomized, controlled trial designed to study the best strategy for treating asymptomatic severe aortic stenosis and ...
FierceBiotech

TCT 2024: Studies show early TAVR procedures help prevent later hospitalizations

WASHINGTON, D.C.—A randomized trial of patients with a narrowing of their heart’s aortic valve, but who had not yet begun to show the symptoms of cardiovascular disease, demonstrated that replacing ...
Business Wire

Groundbreaking Data Demonstrate Superiority of EARLY TAVR in Asymptomatic Severe Aortic Stenosis Patients

WASHINGTON--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced results from the EARLY TAVR Trial, the first randomized, controlled trial designed to study the best strategy for treating ...
Healio

Early TAVR bests surveillance in patients with asymptomatic severe aortic stenosis

Please provide your email address to receive an email when new articles are posted on . TAVR was superior to clinical surveillance in patients with asymptomatic severe aortic stenosis. Almost all ...